SecBot SecBot
Insider Cluster (4 insiders) ·Filed Sep 9, 2026

ARTV

Artiva Biotherapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed2mo ago
Insider cluster: 4 insiders, $0.5M total
Actionable Insight • Neutral

The insider sales are small relative to market cap and follow a large equity grant cycle, making them consistent with routine tax-planning or diversification. Monitor for any upcoming pipeline catalysts (clinical data readouts, regulatory updates) that could explain the timing, but do not read this cluster as a bearish signal on its own.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$10.42
T+0 close · Sep 9, 2026 · via day close
Latest settled
−34.74%
T+20 · $6.80 · next T+60 in 17d
Vs SPY
−37.12%
α at T+20
Latest observation
−55.11%
T+46 · FF3 residual α
  1. T+0 · Sep 10 $10.42entry
  2. T+1 · 2mo ago −1.92%α −2.77% · $10.22
  3. T+5 · 2mo ago −19.00%α −19.63% · $8.44
  4. T+20 · 6w ago −34.74%α −37.12% · $6.80
  5. T+47 · todayOpen
  6. T+60 · in 17d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Four Artiva Biotherapeutics insiders, including the CEO, COO, and CTO, sold a total of ~$477K in open-market shares over a one-week window. These sales follow a cluster of non-cash equity grants to the same executives, suggesting the sales are likely liquidity-driven (tax planning, diversification) rather than signaling a bearish view on the company's pipeline. The total dollar value is ~0.1% of the $500M market cap, falling at the low end of the trivial-to-modest range, and the historical pattern of insider buys at this company has been strongly predictive of upside, not sales. The cross-filing context shows no bearish corporate events (no earnings miss, no restructuring, no late filing) that would amplify the signal, and the actuarial verdicts confirm that insider-sale clusters without such context are not amplified. The net impact is neutral to slightly cautious, but not a material sell signal.

Key Financial Metrics

Direction
selling
Total Value
$477.0K
Insiders
4

Key Facts

  • CEO Fred Aslan sold 23.4K shares for ~$256K on 2026-09-08 at $10.92/share.
  • COO Jennifer Bush sold 8.4K shares for ~$94K on 2026-09-03 at $11.16/share.
  • CTO Christopher Horan sold 10.4K shares for ~$116K on 2026-09-03 at $11.16/share.
  • CMO Subhashis Banerjee sold 1.1K shares for ~$12K on 2026-09-03 at $11.16/share.
  • Total open-market sales of ~$477K represent ~0.1% of the $500M market cap, trivial by proportionality standards.
  • All four executives received large non-cash equity grants (totaling ~856K shares) in the same week, consistent with a standard equity compensation cycle.

Financial Impact

Total insider sales of ~$477K, or ~0.1% of market cap, immaterial from a capital markets perspective.

dilution

Risk Factors

  • Insider sales could accelerate if the stock rallies, creating overhead supply.
  • No open-market insider buying in the cluster, absence of bullish insider conviction.
  • Clinical-stage biotech risk: any pipeline setback could amplify the modest insider selling pattern.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-ARTV-1789432300198

Track record

33 reports on ARTV

Performance horizon

11 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 17 of 19 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
  2. Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
  3. Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
  4. Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
  5. Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
  6. Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  7. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Viewing Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  8. Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  9. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  10. Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
Showing 10 of 33

US Market Status

Market Closed · Opens in 8h 20m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 14, 2026